Suggested remit - To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for unresectable, advanced oesophageal cancer when standard chemotherapy has failed.
 
Status In progress
Process STA 2018
ID number 1249

Provisional Schedule

Expected publication 06 January 2021

Project Team

Project lead Joanne Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Consultees

Companies sponsors Bristol-Myers Squibb (nivolumab)
Others Department of Health
  NHS Durham Dales, Easington and Sedgefield CCG
  NHS Southport and Formby CCG
  NHS England
  Welsh Government
Patient carer groups Black Health Agency
  Cancer Black Care
  Cancer Equality
  Cancer 52
  Equalities National Council
  HAWC
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Oesophageal Patients Association
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Association of Surgical Oncology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society
  British Society of Gastroenterology
  Cancer Research UK

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (docetaxel, irinotecan, paclitaxel)
  Celgene (paclitaxel)
  Genzyme Therapeutics (docetaxel)
  Hospira UK (docetaxel, irinotecan, paclitaxel)
  Medac (docetaxel, irinotecan paclitaxel)
  Pfizer (irinotecan)
  Seacross Pharmaceuticals (docetaxel, irinotecan)
  Servier Laboratories (irinotecan)
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Society of Gastroenterology
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Grampian Gastro-Oesophageal Cancer Research Fund
  Guts UK
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Research Institute of the Care of the Elderly

Timeline

Key events during the development of the guidance:

Date Update
28 November 2019 The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for previously treated oesophageal cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid-February 2020 when we will write to you about how you can get involved.
25 September 2019 - 16 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 2
12 July 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for previously treated oesophageal cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- November 2019 when we will write to you about how you can get involved.
22 March 2019 In progress, As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for previously treated oesophageal cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- August 2019 when we will write to you about how you can get involved.
25 January 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for previously treated oesophageal cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid- March 2019 when we will write to you about how you can get involved.
06 July 2018 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nivolumab for previously treated oesophageal cancer. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early December 2018.
06 February 2018 - 06 March 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance